Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration

Association between Polymorphisms in CFH, ARMS2, CFI, and C3 Genes and Response to Anti-VEGF Treatment in Neovascular Age-Related Macular Degeneration

Neovascular age-related macular degeneration (nAMD) is the leading cause of vision loss in the elderly. The gold standard of nAMD treatment is intravitreal injections of vascular endothelial growth factor (VEGF) inhibitors. Genetic factors may influence the response to anti-VEGF therapy and result i...

Full description

Bibliographic Details
Main Authors:	Oyuna S. Kozhevnikova, Anzhella Zh. Fursova, Anna S. Derbeneva, Ida F. Nikulich, Mikhail S. Tarasov, Vasiliy A. Devyatkin, Yulia V. Rumyantseva, Darya V. Telegina, Nataliya G. Kolosova
Format:	Article
Language:	English
Published:	MDPI AG 2022-07-01
Series:	Biomedicines
Subjects:	age-related macular degeneration neovascularization anti-VEGF therapy regulatory SNP pharmacogenomics
Online Access:	https://www.mdpi.com/2227-9059/10/7/1658

Similar Items

Pharmacogenetic Association between Allelic Variants of the Autophagy-Related Genes and Anti-Vascular Endothelial Growth Factor Treatment Response in Neovascular Age-Related Macular Degeneration
by: Oyuna S. Kozhevnikova, et al.
Published: (2023-11-01)

Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study
by: Jin Jing, et al.
Published: (2018-07-01)

Efficacy of anti-VEGF combined with compound trabeculectomy in the treatment of neovascular glaucoma
by: Cao-Yu Sun, et al.
Published: (2020-09-01)

VEGF-targeting drugs for the treatment of retinal neovascularization in diabetic retinopathy
by: Alessandro Arrigo, et al.
Published: (2022-12-01)

Neovascular Remodeling and Subretinal Fibrosis as Biomarkers for Predicting Incomplete Response to Anti-VEGF Therapy in Neovascular Age-Related Macular Degeneration
by: Jing Wu, et al.
Published: (2022-04-01)

New Therapies of Neovascular AMD—Beyond Anti-VEGFs
by: Praveen Yerramothu
Published: (2018-07-01)

The Architecture of Macular Neovascularizations Predicts Treatment Responses to Anti-VEGF Therapy in Neovascular AMD
by: Henrik Faatz, et al.
Published: (2022-11-01)

Treatment Strategies for Anti-VEGF Resistance in Neovascular Age-Related Macular Degeneration by Targeting Arteriolar Choroidal Neovascularization
by: Yingbin Fu, et al.
Published: (2024-02-01)

Bilateral Hypertensive Retinopathy Complicated with Retinal Neovascularization: Panretinal Photocoagulation or Intravitreal Anti-VEGF Treatment
by: Odysseas Georgiadis, et al.
Published: (2014-07-01)

Results of Intravitreal Anti-VEGF Injection in Choroidal Neovascularization Caused by Pathologies Other Than Age-Related Macular Degeneration
by: Mehmet Ozveren
Published: (2020-08-01)

Use of Bevacizumab in the Treatment of Corneal Neovascularization
by: Tuba Çelik, et al.
Published: (2015-01-01)

The Optimization of an Anti-VEGF Therapeutic Regimen for Neovascular Glaucoma
by: Ling Bai, et al.
Published: (2022-01-01)

Clinical effects of anti-VEGF combined with Ahmed valve implantation and phacoemulsification or not for neovascular glaucoma with cataract
by: Li-Jun Zhao, et al.
Published: (2019-08-01)

Myopic choroidal neovascular membrane: A retrospective study
by: S Sindhu, et al.
Published: (2016-01-01)

Manipulation of autophagy: a novelly potential therapeutic strategy for retinal neovascularization
by: Rong Li, et al.
Published: (2018-04-01)

Impact of Delayed Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapy Due to the Coronavirus Disease Pandemic on the Prognosis of Patients with Neovascular Age-Related Macular Degeneration
by: Jae-Gon Kim, et al.
Published: (2022-04-01)

Intravitreal anti-VEGF treatment for choroidal neovascularization secondary to traumatic choroidal rupture
by: T. Barth, et al.
Published: (2019-11-01)

Peripapillary Choroidal Neovascularization Associated with Optic Nerve Head Drusen Treated with Anti-VEGF Agents
by: Norman A. Saffra, et al.
Published: (2015-02-01)

Myopic choroidal neovascularization with neovascular signal around perforating scleral vessel prone to recur after anti-VEGF therapy
by: Xiangjun She, et al.
Published: (2024-02-01)

A Review of Neovascular Glaucoma: Etiology, Pathogenesis, Diagnosis, and Treatment
by: Danielė Urbonavičiūtė, et al.
Published: (2022-12-01)

Retrospective analysis of anti-VEGF intravitreal injection
by: Hai-Zhi Ma, et al.
Published: (2017-03-01)

5α-Hydroxycostic acid inhibits choroidal neovascularization in rats through a dual signalling pathway mediated by VEGF and angiopoietin 2
by: Wulong Lei, et al.
Published: (2023-11-01)

Outcomes of vitrectomy, complete pan-retinal photocoagulation, and endoscopic cyclophotocoagulation surgery after anti-VEGF treatment in neovascular glaucoma
by: Jinglan Li, et al.
Published: (2023-08-01)

Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration
by: Reem H. ElSheikh, et al.
Published: (2022-11-01)

Efficacy of Intravitreal injection of 2-Methoxyestradiol in regression of neovascularization of a retinopathy of prematurity rat model
by: Azza Mohamed Ahmed Said, et al.
Published: (2017-04-01)

Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options
by: Tan CS, et al.
Published: (2022-03-01)

Temporary Vitelliform Regression After Intravitreal Ranibizumab Injection for Macular Neovascularization Complicating Best Disease
by: Fayed A
Published: (2022-10-01)

Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01)

The progress of assessment methods and treatments of neovascular glaucoma secondary to central retinal vein occlusion
by: Sheng Qu, et al.
Published: (2024-01-01)

Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration
by: O.M. Blavatska, et al.
Published: (2018-02-01)

Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration
by: Marco Nassisi, et al.
Published: (2023-04-01)

Prediction of the short-term efficacy of anti-VEGF therapy for neovascular age-related macular degeneration using optical coherence tomography angiography
by: Huixun Jia, et al.
Published: (2022-05-01)

Efficacy of surgery plus anti-VEGF for the treatment of neovascular glaucoma
by: U.P. Sydorchuk, et al.
Published: (2023-02-01)

A novel small molecule anti-VEGF drug Brolucizumab in the treatment of neovascular age-related macular degeneration
by: Tong Wu, et al.
Published: (2022-05-01)

Perforating scleral vessels adjacent to myopic choroidal neovascularization achieved a poor outcome after intravitreal anti-VEGF therapy
by: Wangjing Yao, et al.
Published: (2022-12-01)

Clinical Features of Untreated Type 2 Macular Telangiectasia and Efficacy of Anti-Vascular Endothelial Growth Factor Therapy in Macular Neovascularization
by: Müge Çoban Karataş, et al.
Published: (2022-02-01)

Difference in aqueous concentration and vitreous mass of cytokines in high myopias with and without choroidal neovascularization
by: Shian Zhang, et al.
Published: (2022-11-01)

Personalized Approach in Treatment of Neovascular Age-Related Macular Degeneration
by: Radina Kirkova, et al.
Published: (2022-09-01)

Presumed Melanocytoma-Associated Choroidal Neovascular Membrane with Hemorrhage Successfully Treated with Intravitreal Aflibercept Injections
by: Austin S. Yu, et al.
Published: (2023-09-01)

Determination of Vascular Endothelial Growth Factor-B Concentrations in Aqueous Humor and Plasma of Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy Patients Before and After Anti-VEGF Therapy
by: Huiying Zhou, et al.
Published: (2022-12-01)